Recommendation ID
TA274/1
Question
NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted.
Any explanatory notes
(if applicable)
None.

Source guidance details

Comes from guidance
Ranibizumab for treating diabetic macular oedema
Number
TA274
Date issued
February 2013

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 27/02/2013